Patient selection is crucial for vaccine therapy success in kidney cancer

Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of ... Author: VJOncology Added: 08/22/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts